Key facts
- CytexOrtho’s last known valuation is $18.6M (Jan 2023).
- It has raised $4.4M; the latest was Later Stage VC in Jun 2026.
- Notable investors include US National Science Foundation, MedTech Innovator, Liquid 2 Ventures, NC Idea, Heinz Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for CytexOrtho
- ·The full record, as it builds
Funding rounds
No funding rounds for CytexOrtho are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CytexOrtho
Developer of regenerative medical technologies designed to treat early joint disease. The company focuses on restoring rather than replacing joints, enabling patients with chronic pain and limited mobility to achieve longer-lasting relief beyond symptom management.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2006
- Employees
- 10
- Website
- cytexortho.com/
- Ownership
- Privately Held (backing)
CytexOrtho doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CytexOrtho shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CytexOrtho in its N-PORT filings yet. We sweep new filings monthly.